News

Julie Johnson, PharmD, director of The Ohio State University Clinical and Translational Science Institute (CTSI) has been selected to join a group of government, academia and industry stakeholders working together to identify critical issues in, and inspire action toward improving, the system of drug discovery, development and translation.

The Microbiome Informatics Webinar Series kicks off Tuesday, February 25, 2025, with Dr. Tom Delmont, a leading expert in microbial ecology and metagenomics. He will be diving into Anvi'o, a powerful open-source platform for microbiome data visualization and analysis.

We are pleased to announce that Dr. Amy Margolis has joined the Clinical and Translational Science Institute (CTSI) as the Co-Director of Workforce Development and Director of the Investigator Career Development and Training Program.

Liz Klein Ph.D, MPH, Ohio State CTSI leadership member, co-authored a recent study that found that quitline coaching significantly helped young adults who vape quit.

 This initiative provides training opportunities at both NCATS and FDA.

Due to the size and complexity of Ohio State’s portfolio of more than 7000 active IRB studies, the transition from Buck-IRB to Huron will occur in phases.

Julie Johnson, PharmD, presented about our UM1 Pilot Program.

Are you aware of these changes from the NIH for 2025 applications and reviews? 

In 1976, at a moment in history when U.S. enrollment of women in medical schools had just climbed to 20%, it is notable that the chronicles of the Association of Clinical Research Professionals (ACRP) describe the first meeting of two nurses who were among the field’s earliest clinical research coordinators, Sarah Boyer and Anne LeSher, as the impetus for the formation of the Association.